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The aminoglycoside 6´-N-acetyltransferases of type Ib (aac(6´)-Ib) gene confers resistance to amikacin, tobramycin, kanamycin, and 
netilmicin but not gentamicin. However, some isolates harboring this gene show reduced susceptibility to amikacin. The European 
Committee on Antimicrobial Susceptibility Testing (EUCAST) recommends a revision of the phenotypic description for isolates har-
boring the aac(6´)-Ib gene. In this study, we determined the aminoglycoside susceptibility profiles of 58 AAC(6´)-Ib-producing En-
terobacter cloacae isolates. On the basis of the CLSI and EUCAST breakpoints, a large proportion (84.5% and 55.2%, respectively) of 
these 58 isolates were found to be susceptible to amikacin. However, among the isolates that were shown to be anikacin-suscepti-
ble according to the CLSI and EUCAST breakpoints, only 30.6% and 18.8% isolates, respectively, could be considered to have inter-
mediate resistance on the basis of the EUCAST expert rules. Further studies should be conducted to determine the aminoglycoside 
susceptibility profiles of aac(6´)-Ib-harboring isolates from various geographic regions and to monitor the therapeutic efficacy of 
amikacin in infections caused by these isolates.
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Resistance to aminoglycosides is usually attributable to 
aminoglycoside-modifying enzymes. Among these, amino-
glycoside 6´-N-acetyltransferases of type Ib [AAC(6´)-Ib], is 
the most common cause of amikacin resistance among mem-
bers of the family Enterobacteriaceae [1]. This enzyme can 
modify amikacin, tobramycin, kanamycin, and netilmicin 
but not gentamicin. Moreover, AAC(6´)-Ib often coexists 
with other antibiotic-inactivating enzymes such as β-lacta-
mases, carbapenemases, and other aminoglycosidases; there-
fore, clinical practitioners should be aware of its significance 
[2, 3].
The expert rules laid down by the European Committee 
on Antimicrobial Susceptibility Testing (EUCAST) suggest 
that if an isolate of the family Enterobacteriaceae is interme-
diate or resistant to tobramycin and susceptible to gentami-
cin and amikacin, then its amikacin susceptibility status 
should be revised from “susceptible” to “intermediate” be-
cause production of acquired AAC(6´)-I may not confer 
phenotypic amikacin resistance. In a previous study, we ob-
served that over 40% of the Enterobacter cloacae isolates had 
the aac(6´)-Ib gene [4]; however, many of the isolates with 
this gene were susceptible to amikacin [4]. Therefore, in this 
study, we determined the aminoglycoside susceptibility pro-
files of aac(6´)-Ib-harboring E. cloacae isolates. Further, we 
investigated the aac(6´)-Ib mutations (Leu119Ser, Leu120Ser, 
Glu167Ala, Phe171Ala, and Tyr166Ala) that are known to 
be associated with the loss of amikacin resistance [5-7].
We had previously collected 178 consecutive, non-dupli-
cate isolates of E. cloacae from specimens obtained at 12 
clinical microbiology laboratories in Korea between March 
2005 and July 2005. The aac(6´)-Ib gene was PCR amplified 
using 2 primers—5´-TTGCGATGCTCTATGGGCTA-´3 
and 5´-CTCGAATGCCTGGCGTGTTT-´3—to obtain a 
482-bp product [8]. In our previous study, all the 178 iso-
lates were analyzed for the presence of aac(6´)-Ib-cr [4]. Of 280     www.kjlm.org
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the 74 E. cloacae isolates that were found to be positive for 
aac(6´)-Ib, 58 were available for this study. For these 58 iso-
lates, the minimum inhibitory concentrations (MICs) of 
amikacin (2-256 mg/L), kanamycin (2-256 mg/L), tobra-
mycin (0.5-64 mg/L), and gentamicin (0.5-64 mg/L) were 
determined by the agar dilution method according to the 
CLSI guidelines [9].
To detect the mutations associated with the loss of amika-
cin resistance, the 482-bp PCR products were sequenced 
using a DNA Analyzer (Applied Biosystems, Foster City, 
CA, USA). To investigate the clonal relatedness of the iso-
lates, pulsed-field gel electrophoresis (PFGE) was performed 
using a CHEF Mapper system (Bio-Rad Laboratories, Her-
cules, CA, USA). The whole-cell DNA was digested with 
XbaI, and the results were interpreted according to the cri-
teria proposed by Tenover et al. [10]. 
Table 1 shows the antibiotic susceptibilities for the isolates. 
Of the 58 isolates harboring the aac(6´)-Ib gene, 49 (84.5%) 
were susceptible to amikacin (≤16 mg/L); 2 (3.4%), to ka-
namycin (≤16 mg/L); 2 (3.4%), to tobramycin (≤4 mg/L); 
and 17 (29.3%), to gentamicin (≤4 mg/L) according to the 
CLSI breakpoints. According to the EUCAST breakpoints, 
32 (52.2%) isolates were susceptible to amikacin (≤8 mg/
L); 2 (3.4%), to tobramycin (≤2 mg/L); and 11 (19%), to 
gentamicin (≤2 mg/L). The distributions of the MICs of 
different aminoglycosides for the 58 E. cloacae isolates are 
shown in Fig. 1 and 2. Of the 49 amikacin-susceptible iso-
lates (MIC ≤16 mg/L), only 2 isolates—KN7 and SO15—
had the Leu119Ser mutation in the aac(6´)-Ib gene. The KN7 
isolate had 1 more amino acid change (Arg173Lys) in this 
gene. Findings of PFGE showed 10 different clones and no 
clonal relatedness among isolates from different clinical mi-
Table 1. Aminoglycoside susceptibilities of the 58 aac(6´)-Ib-harboring Enterobacter 
cloacae isolates
Pheno-
type*
Amikacin N (%) Kanamycin
† 
N (%) Tobramycin N (%) Gentamicin N (%)
CLSI EUCAST CLSI CLSI EUCAST CLSI EUCAST
S  49 (84.5) 32 (55.2) 2 (3.4) 2 (3.4) 2 (3.4) 17 (29.3) 11 (19)
I  1 (1.7) 17 (29.3) 3 (5.2) 2 (3.4)    0 7 (12.1) 6 (10.3)
R  8 (13.8) 9 (15.5) 53 (91.4) 54 (93.1) 56 (96.6) 34 (58.6) 41 (70.1)
*CLSI-recommended minimum inhibitory concentration breakpoints for amikacin and 
kanamycin (S≤/I/R≥) are 16/32/64, and those for tobramycin and gentamicin are 
4/8/16; the corresponding EUCAST breakpoint for amikacin (S≤/R>) are 8/16, and 
those for tobramycin and gentamicin are 2/4; 
†MIC breakpoint for kanamycin was not 
recommended by the EUCAST.
Abbreviations: S, susceptible; I, intermediate; R, resistant; EUCAST, European Commit-
tee on Antimicrobial Susceptibility Testing. 
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Fig. 1. Distribution of the minimum inhibitory concentrations (MICs) of ami-
kacin and kanamycin for the 58 Enterobacter cloacae isolates harboring the 
aac(6´)-Ib gene*.
Black bars, amikacin; hatched bars, kanamycin.
*C1LSI-recommended MIC breakpoints for amikacin and kanamycin (S≤/I/
R≥) are 16/32/64, and the corresponding EUCAST breakpoints for amikacin 
(S≤/R>) are 8/16. 
Abbreviation: EUCAST; European Committee on Antimicrobial Susceptibility 
Testing. 
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Fig. 2. Distribution of the minimum inhibitory concentrations (MICs) of to-
bramycin and gentamicin for the 58 Enterobacter cloacae isolates harboring 
the aac(6´)-Ib gene*.
Black bars, tobramycin; hatched bars, gentamicin.
*CLSI-recommended MIC breakpoints for tobramycin and gentamycin (S≤/
I/R≥) are 4/8/16, and the corresponding EUCAST breakpoints (S≤/R>) are 
2/4. 
Abbreviation: EUCAST; European Committee on Antimicrobial Susceptibility 
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crobiology laboratories. However, clonal relatedness was 
observed among isolates from same hospitals: 2 out of 8, 2 
out of 4, 2 out of 6, 3 and 2 out of 7, 2 out of 6, 2 and 2 out 
of 8, 4 out of 5, and 2 out of 2 isolates collected from 8 clini-
cal microbiology laboratories. The isolates belonging to the 
same clone revealed identical PFGE pattern, but one isolate 
from hospital GM was related. We observed that 19 isolates 
belonging to 8 different clones were susceptible to amikacin 
(MIC ≤16 mg/L) and had different MICs for other amino-
glycosides. However, 4 isolates belonging to the remaining 
2 clones were resistant to all the tested aminoglycosides (MIC 
for amikacin and kanamycin, ≥256 mg/L; MIC for tobra-
mycin and gentamicin, ≥64 mg/L) (data not shown). 
A very high percentage of the aac(6´)-Ib-harboring iso-
lates were susceptible to amikacin (84.5% and 55.2% accor-
ding to the CLSI and EUCAST breakpoints, respectively). 
However, among the isolates that were shown to be amika-
cin-susceptible according to the CLSI and EUCAST crite-
ria, the phenotypes of only 30.6% (15/49) and 18.8% (6/32) 
isolates, respectively, could be revised according to the EU-
CAST expert rules because many of these amikacin-suscep-
tible isolates were resistant to gentamicin. The gentamicin 
resistance may be because of gentamicin-modifying enzymes 
such as AAC(3)-I, AAC(3)-VI, AAC(2´)-I, AAC(3)-IV, Ant 
(2´)-I, and ACC(3)-II or impermeability. Since only 2 iso-
lates had mutations associated with the loss of amikacin re-
sistance, we think that the remaining isolates might have 
produced low-levels of AAC(6´)-Ib. Low levels of AAC(6´)-Ib 
could not confer resistance to amikacin and isepamicin in 
vitro but were able to efficiently modify the small amounts 
of drug entering the bacterial cell and thereby conferred re-
sistance in vivo. Therefore, a previous study did not report 
any noticeable difference in the in vivo efficacies of amika-
cin or isepamicin for low- and high-level AAC(6´)-Ib-pro-
ducing organisms [11]. 
Our results show that the MICs of amikacin for many 
AAC(6´)-Ib-producing isolates were below the susceptibil-
ity breakpoints recommended by the CLSI or EUCAST and 
that most of these susceptible isolates could not be consid-
ered to have intermediate amikacin resistance according to 
the above-mentioned EUCAST expert rules. Data on the 
epidemiology and optimal therapy of infections caused by 
these strains are scarce; therefore, further studies are needed 
to characterize these infections. 
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